Eucrisa Approval History
- FDA approved: Yes (First approved December 14th, 2016)
- Brand name: Eucrisa
- Generic name: crisaborole
- Dosage form: Topical Ointment
- Company: Pfizer Inc.
- Treatment for: Atopic Dermatitis
Eucrisa (crisaborole) is a novel, non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor indicated for the treatment of mild-to-moderate atopic dermatitis.The approval of Eucrisa was based the results of two large clinical trials (Trials 1 and 2) that treated 1,522 patients with mild to moderate atopic dermatitis. In both trials, patients were randomized to receive Eucrisa or vehicle (non-medicated ointment) twice daily for 28 days. Data showed Eucrisa to be an effective treatment that achieved statistically significant results, with a greater number of patients reporting clear or almost clear skin at the end of the trial period, with some achieving success as early as day eight.
Eucrisa is applied as a thin layer to the affected areas twice daily. Common side effects include pain at the application site, such as burning or stinging.
Development History and FDA Approval Process for Eucrisa
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.